Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00295685

Recruitment Status : Completed

First Posted : February 24, 2006

Last Update Posted : February 25, 2009

Sponsor:

Collaborator:

AstraZeneca

Information provided by:

Digestive & Liver Disease Specialists

Study Description

Brief Summary:

The purpose of this study is to determine if people taking lansoprazole two times a day to control severe GERD symptoms can be controlled just as well, if not better, by taking Nexium just once a day.

Condition or disease	Intervention/treatment	Phase
GERD	Drug: Antacids	Phase 4

Detailed Description:

approximately 20% of patients taking first generation proton pump inhibitors (PPIs) are taking more than the standard approved dose. This dosing is required to attain adequate control of the gastric and intraesophageal pH in order to affect the desired clinical improvement. It is recognized that the b.i.d dosing strategy increases the intragastric pH control of <4 from approximately 12 hours to almost 16 hours. The refinement of the S isomer of omeprazole (Nexium)has led to a way to more effectively control acid exposure. Comparative trials with all the PPIs have shown significantly greater pH control of <4 and head to head comparisons as well as a recent crossover study. One study suggests that Nexium dosing contains approximately 16.5 hours of a pH control of <4. Conceivably, this duration of pH control suggests that b.i.d. dosing of other PPIs might be avoided. Furthermore, it suggests that patients currently taking b.i.d. PPIs might be successful candidates for conversion to q.d. Nexium. This would provide a considerable cost implication to health care plans and for patients who are responsible for paying for their PPI therapy. To date, esomeprazole has not been studied in comparison to b.i.d. dosing with other PPIs. There is pharmacologic evidence to suggest, however, that it is comparable. In this proposed study, we believe that by beginning with patients who were well controlled should make for a cleaner definition and a higher likelihood to demonstrate efficacy.

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	50 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study
Study Start Date :	October 2005
Study Completion Date :	December 2007

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

The proportion of subjects who are successfully stepped-down to single-dose PPI therapy, defined as having no recurrence of heartburn or acid regurgitation 3 months after PPI step-down.

Secondary Outcome Measures :

Changes in GERD symptom scores, health related quality of life, ancillary medication expenditures, and predictors of successful step-down.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Previous diagnosis of severe GERD.
Male or female 18-80 years of age
Ability to read, understand and provide informed consent
GERD is Adequately controlled on BID lansoprazole as evidenced by GERD-HRQL score of </= 11
Females of childbearing potential must use an acceptable method of birth control for the duration of the study.

Exclusion Criteria:

Known contraindications to Nexium
Current or historical evidence of >3 cm histologically confirmed Barrett's metaplasia without current dysplasia, esophageal stricture or extraesophageal GERD symptoms.
Previous Esophageal gastric surgery
Pregnant or nursing Females
Clinically significant abnormal laboratory values
Medical condition that may be adversely impacted by participation in this study
History of or current drug or alcohol abuse
Known malignancy
Need for concurrent therapy with any acid suppressive therapy other than the study drug, antacids, alginates, NSAIDS, >165 mg ASA, prostaglandin analogs, prokinetic drug, antineoplastic agents, Ketoconazole, Itraconazole, Voriconazole, Clarithromycin, Telithromycin, HIV protease inhibitors, Rifampin, Phenobarbital, or Digoxin
Use of investigational drug or experimental device within 30 days prior to screening

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295685

Locations


United States, Virginia
Digestive & Liver Disease Specialists
Norfolk, Virginia, United States, 23502

Sponsors and Collaborators

Digestive & Liver Disease Specialists

AstraZeneca

Investigators


Principal Investigator:	David A Johnson, MD	Digestive & Liver Disease Specialists

More Information


ClinicalTrials.gov Identifier:	NCT00295685 History of Changes
Other Study ID Numbers:	IRUSESOM0159
First Posted:	February 24, 2006 Key Record Dates
Last Update Posted:	February 25, 2009
Last Verified:	February 2009

Keywords provided by Digestive & Liver Disease Specialists:


Reflux GERD

Additional relevant MeSH terms:


Antacids Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents

To Top